US-headquartered research and discovery firm Beckman Coulter Life Sciences has acquired the flow cytometry business assets of Bangalore-based life science technology company ReaMetrix India Pvt Ltd for an undisclosed amount.
The deal will help Beckman Coulter expand its reach in two key segments of cell analysis – HIV monitoring and clinical research.
“This acquisition provides both immediate opportunity and long-term value. We’ll be able to offer customers an extended line of market-leading technologies while expanding our reach within two key segments for flow cytometry – HIV monitoring and clinical research,” said Mario Koksch, vice-president and general manager of the cytometry business unit at Beckman Coulter Life Sciences.
ReaMetrix products complement Beckman’s flow cytometry portfolio with reagents that will simplify the sample preparation process and provide highly standardised reagent combinations to cytometry laboratories around the globe, according to a release issued by the company.
“Over the last decade, ReaMetrix has been developing technologies that improve access of diagnostic testing through innovation. The development of room temperature-stable, unitised flow reagents used in diagnostics and life sciences is an important component of that effort. For ReaMetrix, Beckman Coulter Life Sciences represents an opportunity to provide the global customer with an integrated and optimised solution involving both hardware and reagents,” said Bala S. Manian, CEO of ReaMetrix.
ReaMetrix products are among the first dry temperature-stable flow cytometry reagents marked for in-vitro diagnostic use in Europe, but these are not currently available or cleared for use in the US.
(Edited by Sanghamitra Mandal)